Navigation Links
Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Date:9/5/2007

Very Robust Findings on the Key Problems Faced by Insomniacs, i.e. Sleep Onset and Sleep Maintenance

Evotec to Host a Conference Call Today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) Directly From the Worldsleep07 Congress in Australia

HAMBURG, Germany and OXFORD, England, September 5 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) presented today at the worldsleep07 congress in Cairns, Australia the details of the results from its first Phase II clinical trial of EVT 201 in patients with primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blind, placebo controlled cross-over study of two doses of EVT 201 (1.5mg and 2.5mg) in 67 completed patients was conducted in sleep labs in the US using objective polysomnography (PSG). After having published top-line results in a press release on 4 June 2007, the results of the detailed analysis are herewith reported.

The detailed analysis showed that all endpoints achieved an even higher level of statistical significance than first indicated. The pre-specified intention-to-treat analysis of the study showed that on both of the co-primary endpoints of Total Sleep Time (TST) and Wake After Sleep Onset (WASO) the statistical significance of both doses against placebo was p<0.0001.

Highly statistically and clinically meaningful effects were also found on both the Latency to Persistent Sleep (LPS) and TST in the second half of the night, indicating strong effects on both sleep onset and sleep maintenance. In addition to these objective PSG results, there were highly significant improvements, at both dose levels, on the subjective perception of sleep quality.

The following morning there was no subjective perception of any residual sedation. The Digit Symbol Substitution Test (DSST) showed a small but clinically insignificant change tested the next day 9 h after dosing.

The PSG analysis al
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... Bruno, CA. (PRWEB) , ... July 29, 2015 ... ... agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical ... advisory services, and patient recruitment services. The core expertise of PRC Clinical is ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... new "gold standard" in the sensitivity of weighing scales. ... world,s first fully functional nanotube radio, researchers with Berkeley ... have fashioned a nanoelectromechanical system (NEMS) that can function ... of a single atom of gold. , Alex Zettl, ...
... Inc. (NYSE: MYL ),today announced that its ... the U.S. Food and Drug Administration (FDA),for its ... Tablets, 20 mg, 30 mg and 40 mg., ... of hypertension,are the generic version of Sciele Pharma,s ...
... Fred Alger Management, Inc. (Alger),a leading asset management ... as Vice President, Senior Analyst/Co-Portfolio Manager for,Alger covering ... industries., David received his Doctor of Medicine ... Chief Medical Resident. While in Pennsylvania David,served as ...
Cached Biology Technology:Golden scales 2Golden scales 3David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager 2
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Farrow and Zafer Iqbal, research professors at NJIT, were ... fabricating arrays of nanoscale electrical probes. Their discovery ... spatial variation of electrical activity inside biological cells. ... array technique that allows for an array of individual, ...
... Missouri officials announced today a $5 million grant agreement ... Translational Partnership Award Program. The goal of the partnership ... improve patient lives and suffering from any disease or ... will be used to support collaborative projects between biomedical ...
... assessment, written by WCS Senior Conservation Scientist Dr. John ... information on these species and how climate change ... region and from nearly 300 scientific papers. In ... through these remote roadless areas to evaluate their importance ...
Cached Biology News:Patent for arrays of nanoscale electrical probes awarded to NJIT today 2MU signs $5 million agreement with Coulter Translational Research Partnership Program 2MU signs $5 million agreement with Coulter Translational Research Partnership Program 3Where will grizzly bears roam? 2
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
... (AChE) activity. This is a highly sensitive, ... and easy to use assay for AChE ... A series of coupled enzyme reactions translates ... change in luminescence. Inhibitors of AChE are ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: